FSC-2023
15.3.2023 16:48:34 CET | Business Wire | Press release
The second edition of the Financial Sector Conference (FSC 2023) opened today in Riyadh, welcoming over 3000 participants from around the world to discuss the way ahead for the global financial community under the conference theme of “Promising Financial Prospects.”
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230315005659/en/
Saudi Minister of Finance HE Mohammed Al-Jadaan addresses delegates at opening of Financial Sector Conference in Riyadh, Saudi Arabia (Photo: AETOSWire)
Welcoming delegates to the conference Saudi Minister of Finance HE Mohammed Al-Jadaan said: “I am confident that this conference will be an opportunity to build on experiences and share ideas to address a global economy which is full of challenges and opportunities—helping to make the global financial sector stronger, more influential and resilient.”
The conference opened with a powerful panel discussion examining the strategic options for the financial sector in light of challenging global economic circumstances. Credit Suisse Group AG Chairman Axel Lehmann told the audience: “What is clear is that over the past 10 to 15 years the massive geopolitical shifts we have seen are generating new economic opportunities in places like the Middle East which is becoming a vibrant new global centre along with places such as China and India.”
Commenting on opportunities emerging in Saudi Arabia, State Street Chairman and CEO Ronald O’Hanley added: “For investors it is clearly a very attractive time to be here with a strong economy and a Government that is committed to transition and powered by a well-educated workforce. There are clear investment opportunities in energy and renewables, in tourism and to benefit from the rise in the consumer economy.”
HE Eng. Khalid Al Falih, Saudi Arabia’s Minister of Investment, said: “We are now halfway to implementing Vision 2030 that will triple the scale of the economy and we are ahead of schedule but we know we cannot be complacent. One of the biggest shifts emerging is that in the past we were seen as a source of capital but that is being reversed today and we are urging the financial community to be aware of the opportunities and we aim to attract more capital and international partners.”
Alexandre Fleury, Co-Head of Market Activities, Societe Generale, told the conference: “Vision 2030 is extraordinary and an amazing achievement. But the world has not noticed enough what is happening in Saudi Arabia but soon investors will have no choice but to invest here. Global investors have to be a part of Vision 2030.”
Looking at the global economic situation, Seth Carpenter, Global Chief Economist, Morgan Stanley, “As Morgan Stanley, we are pretty optimistic about Asia, specifically China, Japan, India and Saudi Arabia. The weakest growth is in Europe and the US although economic performance is high. The quandary for central banks is how much you raise interest rates in order to bring inflation down; and judging exactly how much you need to slow things down without causing a recession.”
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005659/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit
Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse
Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 16:37:00 CEST | Press release
Compass is the most advanced company in classic psychedelics and has generated positive data from two ongoing large, well controlled Phase 3 clinical trials, designed to uphold the highest regulatory standardsFDA grants Compass NDA rolling submission and review request, based on Phase 3 dataCNPV awarded for COMP360, Compass’ proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD)CNPV further accelerates momentum and Compass is confident and ready to deliver for patients Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be en
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
